FDA Drug Safety Board To Meet Every Six Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
The board discussed FDA's recent action on fentanyl transdermal patches (J&J's Duragesic and generics) and Purdue's Palladone (hydromorphone extended-release) during a July 27 meeting, FDA's meeting summary says.
You may also be interested in...
FDA Drug Safety Oversight Board Should Have More Independent Outside Advisors, Cmte. Says
Board Executive Director Susan Cummins maintains that as a "management tool," the DSOB must run in a different way from a public advisory committee.
FDA Drug Safety Oversight Board Should Have More Independent Outside Advisors, Cmte. Says
Board Executive Director Susan Cummins maintains that as a "management tool," the DSOB must run in a different way from a public advisory committee.
FDA Public Meeting On Drug Safety Communication Set For Dec. 7-8
Agency seeks public input on effectiveness of currently used risk communication tools; meeting is part of ongoing drug safety initiative.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: